Bavar­i­an Nordic con­tin­ues to in­crease 2022 rev­enue pro­jec­tions as mon­key­pox spreads

The spread of mon­key­pox, al­though not on the scale of the on­go­ing Covid-19 pan­dem­ic, has helped Dan­ish drug­mak­er Bavar­i­an Nordic ben­e­fit from its small­pox vac­cine.

As a re­sult of vac­cine or­ders from around the world, Bavar­i­an Nordic is rais­ing its an­nu­al guid­ance yet again, now pre­dict­ing be­tween DKK 1.4 bil­lion and 1.6 bil­lion in rev­enue this year, or rough­ly $200 mil­lion to $229 mil­lion. That’s slight­ly up from last week, when the com­pa­ny pegged 2022 rev­enues at DKK 1.3 bil­lion to 1.5 bil­lion, or $186 mil­lion to $215 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER